Skip to main content
Top
Published in: Virology Journal 1/2023

Open Access 01-12-2023 | Hepatitis B | Research

A noninvasive model discriminating significant histological changes in treatment-naive chronic hepatitis B patients with normal ALT

Authors: Jiaming Teng, Yanan Du, Phimphone Visalath, Tianhui Zhou, Bingying Du, Qin Zhang, Wei Cai

Published in: Virology Journal | Issue 1/2023

Login to get access

Abstract

Background

Traditionally part of chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT) are recommended to antiviral therapy referring to liver biopsy. However, liver biopsy is an invasive method with various potential complications. A noninvasive model was established in the study to evaluate liver histology and to identify the need of antiviral therapy.

Methods

A total of 614 liver biopsied CHB patients with ALT less than upper limit of normal from 2 centers were retrospectively analyzed. They were divided into a training cohort and a validation cohort. A noninvasive model to predict the significant liver histological changes was established and validated.

Results

The results of analysis showed that ALT, Age, platelet (PLT) and liver stiffness (LS) were independent risk factors for significant liver injury. The model was established based on the 4 indexes, with the area under the curve of 0.85 and 0.87 in training cohort and validation cohort. Meanwhile, 2 cut-off scores were selected. By applying the low cut-off score (− 0.207), patients without significant liver injury could be identified with high accuracy, with negative predictive value of 72.7% and 73.7% in training and validation cohorts. By applying the high cut-off score (0.537), the presence of significant liver injury could be diagnosed with high accuracy, with positive predictive value of 90.3% and 88.8% in the training and validation cohorts. By applying the model, liver biopsy would have been avoided in 87.6% (538/614) patients, with correct prediction in 87.9% (473/538).

Conclusion

The novel noninvasive model composed of ALT, Age, PLT, LS can correctly assess liver histology in CHB patient with normal ALT, which helps to determine the need of antiviral therapy without liver biopsy.
Appendix
Available only for authorised users
Literature
1.
go back to reference The Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.CrossRef The Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.CrossRef
2.
go back to reference Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet (London, England). 2016;388(10049):1081–8. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden of disease study 2013. Lancet (London, England). 2016;388(10049):1081–8.
3.
go back to reference Xu Y, Liu H, Wang Y, et al. The next step in controlling HBV in China. BMJ (Clin Res Ed). 2013;347:f4503. Xu Y, Liu H, Wang Y, et al. The next step in controlling HBV in China. BMJ (Clin Res Ed). 2013;347:f4503.
4.
go back to reference Wong MCS, Huang JLW, George J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16(1):57–73.CrossRef Wong MCS, Huang JLW, George J, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16(1):57–73.CrossRef
5.
go back to reference Chen Y, Tian Z. HBV-induced immune imbalance in the development of HCC. Front Immunol. 2019;10:2048.CrossRef Chen Y, Tian Z. HBV-induced immune imbalance in the development of HCC. Front Immunol. 2019;10:2048.CrossRef
6.
go back to reference Vlachogiannakos J, Papatheodoridis GV. Hepatitis B: Who and when to treat? Liver Int. 2018;38(Suppl 1):71–8.CrossRef Vlachogiannakos J, Papatheodoridis GV. Hepatitis B: Who and when to treat? Liver Int. 2018;38(Suppl 1):71–8.CrossRef
7.
go back to reference McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology (Baltimore MD). 2009;49(5 Suppl):45–55.CrossRef McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology (Baltimore MD). 2009;49(5 Suppl):45–55.CrossRef
8.
go back to reference Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology (Baltimore MD). 2018;67(4):1560–99.CrossRef Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology (Baltimore MD). 2018;67(4):1560–99.CrossRef
9.
go back to reference Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology (Baltimore MD). 2016;63(1):261–83.CrossRef Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology (Baltimore MD). 2016;63(1):261–83.CrossRef
10.
go back to reference EASL. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.CrossRef EASL. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.CrossRef
11.
go back to reference Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology (Baltimore MD). 2009;49(3):1017–44.CrossRef Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology (Baltimore MD). 2009;49(3):1017–44.CrossRef
12.
go back to reference Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319–34.CrossRef Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319–34.CrossRef
13.
go back to reference Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology (Baltimore MD). 2017;66(5):1486–501.CrossRef Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology (Baltimore MD). 2017;66(5):1486–501.CrossRef
14.
go back to reference Du B, Teng J, Yin R, et al. Increased circulating T follicular helper cells induced via IL-12/21 in patients with acute on chronic hepatitis B liver failure. Front Immunol. 2021;12:641362.CrossRef Du B, Teng J, Yin R, et al. Increased circulating T follicular helper cells induced via IL-12/21 in patients with acute on chronic hepatitis B liver failure. Front Immunol. 2021;12:641362.CrossRef
15.
go back to reference Sumsion GR, Bradshaw MS III, Beales JT, et al. Diverse approaches to predicting drug-induced liver injury using gene-expression profiles. Biol Direct. 2020;15(1):1.CrossRef Sumsion GR, Bradshaw MS III, Beales JT, et al. Diverse approaches to predicting drug-induced liver injury using gene-expression profiles. Biol Direct. 2020;15(1):1.CrossRef
16.
go back to reference Zhou K, Gao CF, Zhao YP, et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2010;25(9):1569–77.CrossRef Zhou K, Gao CF, Zhao YP, et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2010;25(9):1569–77.CrossRef
17.
go back to reference Chan SL, Wong VW, Qin S, et al. Infection and cancer: the case of hepatitis B. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(1):83–90.CrossRef Chan SL, Wong VW, Qin S, et al. Infection and cancer: the case of hepatitis B. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(1):83–90.CrossRef
18.
go back to reference Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore MD). 2018;67(1):358–80.CrossRef Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology (Baltimore MD). 2018;67(1):358–80.CrossRef
19.
go back to reference Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.CrossRef Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.CrossRef
20.
go back to reference Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29(Suppl 1):100–7.CrossRef Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int. 2009;29(Suppl 1):100–7.CrossRef
21.
go back to reference Lau GK. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int. 2010;30(4):512–20.CrossRef Lau GK. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int. 2010;30(4):512–20.CrossRef
22.
go back to reference Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology (Baltimore MD). 2002;35(6):1522–7.CrossRef Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology (Baltimore MD). 2002;35(6):1522–7.CrossRef
23.
go back to reference Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology (Baltimore, Md). 2007;45(2):507–39.CrossRef Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology (Baltimore, Md). 2007;45(2):507–39.CrossRef
24.
go back to reference Neuberger J, Patel J, Caldwell H, et al. Guidelines on the use of liver biopsy in clinical practice from the british Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut. 2020;69(8):1382–403.CrossRef Neuberger J, Patel J, Caldwell H, et al. Guidelines on the use of liver biopsy in clinical practice from the british Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut. 2020;69(8):1382–403.CrossRef
25.
go back to reference Sporea I, Sirli R, Deleanu A, et al. Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis: a comparative study. World J Gastroenterol. 2010;16(38):4832–7.CrossRef Sporea I, Sirli R, Deleanu A, et al. Liver stiffness measurements in patients with HBV vs HCV chronic hepatitis: a comparative study. World J Gastroenterol. 2010;16(38):4832–7.CrossRef
26.
go back to reference Wang CY, Deng Y, Li P, et al. Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: a large multicenter study. Hepatology (Baltimore MD). 2022;75(6):1373–85.CrossRef Wang CY, Deng Y, Li P, et al. Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: a large multicenter study. Hepatology (Baltimore MD). 2022;75(6):1373–85.CrossRef
27.
go back to reference Du Y, Du B, Fang X, et al. ALT Flare predicts hepatocellular carcinoma among antiviral treated patients with chronic hepatitis B: a cross-country cohort study. Front Oncol. 2020;10:615203.CrossRef Du Y, Du B, Fang X, et al. ALT Flare predicts hepatocellular carcinoma among antiviral treated patients with chronic hepatitis B: a cross-country cohort study. Front Oncol. 2020;10:615203.CrossRef
28.
go back to reference Tao X, Chen L, Zhao Y, et al. A novel noninvasive diagnostic model of HBV-related inflammation in chronic hepatitis B virus infection patients with concurrent nonalcoholic fatty liver disease. Front Med. 2022;9:862879.CrossRef Tao X, Chen L, Zhao Y, et al. A novel noninvasive diagnostic model of HBV-related inflammation in chronic hepatitis B virus infection patients with concurrent nonalcoholic fatty liver disease. Front Med. 2022;9:862879.CrossRef
29.
go back to reference Kang NL, Zhang JM, Lin MX, et al. Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients. World J Gastroenterol. 2020;26(27):3952–62.CrossRef Kang NL, Zhang JM, Lin MX, et al. Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients. World J Gastroenterol. 2020;26(27):3952–62.CrossRef
30.
go back to reference Chen S, Huang H, Huang W. A noninvasive model to predict liver histology for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase < 2 upper limit of normal. BMC Gastroenterol. 2021;21(1):4.CrossRef Chen S, Huang H, Huang W. A noninvasive model to predict liver histology for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase < 2 upper limit of normal. BMC Gastroenterol. 2021;21(1):4.CrossRef
31.
go back to reference EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.CrossRef EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.CrossRef
32.
go back to reference Zoulim F. Assessment of treatment efficacy in HBV infection and disease. J Hepatol. 2006;44(1 Suppl):95–9.CrossRef Zoulim F. Assessment of treatment efficacy in HBV infection and disease. J Hepatol. 2006;44(1 Suppl):95–9.CrossRef
Metadata
Title
A noninvasive model discriminating significant histological changes in treatment-naive chronic hepatitis B patients with normal ALT
Authors
Jiaming Teng
Yanan Du
Phimphone Visalath
Tianhui Zhou
Bingying Du
Qin Zhang
Wei Cai
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Hepatitis B
Published in
Virology Journal / Issue 1/2023
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-023-01963-x

Other articles of this Issue 1/2023

Virology Journal 1/2023 Go to the issue